Apligraf for Bullous Ulcers
Endermology or LPG
Methotrexate and Glucocorticoids
Phototherapy, UVA, PUVA
Tacrolimus Cream: Warning
UVA1 phototherapy is now the recommended first-line treatment for morphea.
Many cases of typical plaque morphea entail only one or two “mild” morphea plaques which are not rapidly growing or spreading; are not on the face; are not over joints; and are only on the surface and not digging down deep into muscles and other tissues. Such cases typically do not require treatment, and will likely improve within two or three years, even without any treatment.
Morphea in adults and children cohort II: Patients with morphea experience delay in diagnosis and large variation in treatment. Patients with morphea experience delay in diagnosis, which likely impacts outcome. Many treatments with little or no proven efficacy are used, whereas others with proven efficacy are underused. PubMed, J Am Acad Dermatol, 2012 Nov;67(5):881-9.
UVA1 Phototherapy: A Concise and Practical Review. Phototherapy is an effective therapeutic option in scleroderma and should be considered among the first approaches in the management of localized scleroderma or morphea. UVA1 phototherapy has also been used for patients with limited and diffuse systemic sclerosis. SkinTherapyLetter, 06/21/12. (Also see Skin Fibrosis)
Rarer types of morphea, or those that are rapidly spreading, highly visible, over joints, or growing deep into underlying tissues may require prompt and more aggressive treatment to prevent the spread of plaques and to minimize damage from the disease, since the more severe cases of morphea may cause permanent disfigurement or disability.
Since all types of scleroderma are rare, most physicians may see only one or two cases in an entire career. Thus, it is very difficult for them to identify, categorize, and responsibly advise and treat morphea patients.
There are a few dozen centers in the world that specialize in scleroderma, and of those, only a few treat children. (See Scleroderma Experts)
See the ISN Scleroderma Experts section, where each center is identified as to whether or not they treat adults and/or juveniles, and whether or not they treat localized forms of scleroderma, such as morphea and linear.
Very few of the expert centers treat children with localized scleroderma. Since the consequences of untreated morphea can be severe in some cases, it is important to seek expert advice as soon as possible.
ISN's Voices of Scleroderma Volume 1 book features juvenile scleroderma expert, Dr. Thomas Lehman, who wrote the medical overview of juvenile scleroderma. It also features chapters of true stories by juvenile scleroderma patients and caregivers.Voices of Scleroderma Volume 1 features juvenile scleroderma expert Dr. L. Nandini Moorthy, who wrote the medical overview of juvenile scleroderma. It also features many true stories of patients and caregivers of juvenile scleroderma, morphea, and linear scleroderma. It is an excellent all-around book for patients and caregivers!
Voices of Scleroderma Volume 3 features juvenile scleroderma expert Dr. Fernanda Falcini of Italy, who wrote the medical overview of juvenile scleroderma. It also features many true stories of patients and caregivers of juvenile scleroderma, morphea, and linear scleroderma. It is another excellent all-around book for patients and caregivers!
Conditions Associated with Morphea Scleroderma. About 25% of morphea patients will have at least one extra-cutaneous (non-skin) manifestation, but less than 4% of morphea patients will develop more than two non-skin manifestations. Therefore patients with morphea should receive an annual physical exam to monitor for any additional symptoms which may develop. They should also be tested for anticentromere antibodies (ACA), since the presence of ACA antibodies identifies the very small percentage of morphea patients who are at risk for progressing to systemic sclerosis. ISN.
Cancer: T-Cell Lymphoma
Ulcers caused by bullous morphea treated with tissue-engineered skin. We report a patient with bullous morphea with long-standing ulcers whom we successfully treated with the tissue-engineered skin Apligraf (Organogenesis Inc., Canton, MA). The patient experienced rapid improvement in granulation tissue and the ulcers healed 4 months after a single application. PubMed, Int J Dermatol 2003 May;42(5):402-4.
Localized scleroderma and zinc: a pilot study. We conclude that high-dose zinc gluconate can therefore be a valuable alternative treatment for localized scleroderma, with good tolerability, although placebo-controlled studies are necessary to confirm our results. Brocard A. Eur J Dermatol, 2010 Feb 2. (PubMed). (Also see Alternative Therapies)
Camouflage makeup, or stage and screen makeup may be effective for temporary coverage of morphea patches, on the face or body. This type of makeup can hold up under tough conditions like swimming. When properly applied, it won't wear off on clothing, and a single application can last for days.
Dermacolor Camouflage by Kryolan makeup is an example of longlasting professional makeup, as used by actors and models. When properly applied, it can provide suitable coverage for skin colorations such as telangiectasia, birth marks, and morphea scleroderma. (Also see Telangiectasia, Corrective Cosmetics)
Effectiveness of LPG(R) treatment in morphea. The LPG(R) technique, also known as Endermology(R) treatment, is a noninvasive technique consisting of a tissue mobilization process in which a skin fold is created between two rollers, stretching the underlying tissue and mobilizing the fold. It is an adjunctive treatment for morphea. It cannot eliminate the disease but can relieve the pain, soften the skin and improve the quality of life for these patients. PubMed, J Eur Acad Dermatol Venereol. 2004 Sep;18(5):527-30.
Use of Imiquimod Cream 5% in the Treatment of Localized Morphea. In this case report, imiquimod cream 5% (Aldara®), which induces interferon and in turn inhibits TGF-beta, was employed to treat morphea. PubMed, J Cutan Med Surg. 2004 May 3.
Laser Doppler flowmetry (LDF) for assessing localized scleroderma in children. LDF is a helpful, noninvasive diagnostic technique that can be used to discriminate disease activity in children with localized scleroderma, and is more accurate than thermography for this purpose. Weibel L. (PubMed) Arthritis Rheum. 2007 Oct;56(10):3489-95.
It is very wise to consult a scleroderma expert for guidance in determining which cases may require this treatment and to establish the treatment protocol.
Long-Term Methotrexate Efficacy in Juvenile Localized Scleroderma. Methotrexate (MTX) shows a prolonged efficacy in patients with juvenile localized scleroderma (JLS), with partial or complete remissions sustained in most of the patients, even after two years. Pediatric Rheumatology 2011, 9(Suppl 1):O16.
Development Of An Activity Index For Localized Scleroderma (Morphea). This pilot study provided evidence that a combined therapy of methotrexate and low dose steroids may be effective to treat morphea. Further studies on larger cohort of patients are needed to validate this activity index. E. Lanciano. EULAR 2011 FR10406. Ann Rheum Dis 2011;70(Suppl3):481.
For UVA1 treatment, first contact your scleroderma expert to see if it they will recommend it for you. If they recommend and prescribe it for you, try to find UVA1 facilities near you. Some dermatology offices (usually large offices or with major health centers) have UVA1 equipment (not UVB). It may also be possible to buy UVA1 phototherapy equipment for home use. It is manufactured by Daavlin and distributed worldwide. Home users must be monitored by a physician, who will prescribe the necessary dosage and monitor for possible side-effects, such as skin cancer.
Recurrence of morphea after successful ultraviolet A1 phototherapy: A cohort study. With the exception of increased duration of morphea, risk of recurrence is no different in adults and children, or between morphea subtypes, skin types, and medium- to high-dose regimens. This indicates treatment doses in the medium-high UVA1 range are adequate with respect to frequency of recurrence. Journal of the American Academy of Dermatology, 12/23/2013.
Low-dose UVA1 phototherapy for scleroderma: what benefit can we expect? In patients with morphea, a marked improvement was found in 77.8% patients and a moderate improvement was found in 11.1% patients. In the systemic scleroderma group, a patient with complete remission of the skin sclerosis is emphasized. PubMed, J Eur Acad Dermatol Venereol, 2012 May;26(5):619-26. (Also see Skin Fibrosis Treatments)
Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. UVA1 is currently underprovided, and the recommendation of the workshop is that more tertiary centres should have access to UVA1 phototherapy in the UK. PubMed, 04/2012.
(Expired Article) FDA Public Health Advisory. Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment. There is a potential cancer risk from use of Elidel (pimecrolimus) and Protopic (tacrolimus). It may take ten years or longer to determine if they are linked to cancer. Elidel and Protopic should be used only as labeled, for patients who have failed treatment with other therapies. Medscape 03/10/05.
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Michele Maxson, John Moffett, Joan-Marie Permison, John Roberts, Margaret Roof, and Maryellen Ryan.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.